The main objective of this Feasibility Analysis was to study and evaluate the viability of HyperQTotal from a technical, commercial and financial point of view, our ultimate goal being the validation of the higher efficacy and diagnostic value of high frequency electrocardiogram (HF-ECG) analysis over conventional stress-ECG tests for Coronary Artery Disease (CAD) and consequent market launch.
We have conducted this feasibility analysis by contacting potential clients, partners and hospitals who could assist us in the execution of the clinical validation study that is foreseen in a consecutive Phase 2 project. Central issue in this feasibility analysis was the question how HyperQTotal could be commercially launched in the most optimal manner, considering the CAD diagnostics market and purchasing power by its stakeholders. Moreover, we have considered several business and revenue models.
An estimation of the cost-effectiveness of implementing HyperQTotal for diagnosis of CAD demonstrated a potential reduction of 13% in unnecessary cardiac imaging tests and of 4% in superfluous coronary angiography procedures. Additionally, indirect costs savings related to better prognosis should be considered as well as the social impact on patients and their families.
HyperQTotal can be implemented on half of the existing ECG-hardware available (about 60% of all currently used computer-based systems) and only involves software for collecting and analysing the HF-data of the ECG and converting this data into useful information for any cardiologist, who will only need short training in interpretation of the HF-QRS information. It will be offered primarily to cardiologists and hospitals on a Pay-per-Test basis by providing it as a cloud service.
